Neha S Gandhi |
|
B.E.,M.Phil., Ph.D.
|
| a |
| a |
| a |
| a |
24.59
Skills (22)
-
82 Questions3094 Followers
-
56 Questions1237 Followers
-
75 Questions2268 Followers
-
1 Question22 Followers
-
46 Questions51 Followers
-
5 Questions6 Followers
-
0 Questions17 Followers
-
13 Questions15 Followers
-
1 Question89 Followers
-
0 Questions3 Followers
-
41 Questions3395 Followers
-
18 Questions724 Followers
-
33 Questions4928 Followers
-
0 Questions32 Followers
-
125 Questions7820 Followers
Research experience
-
Sep 2012–
presentResearch: Curtin Research Fellow
Curtin University Australia · Curtin Health Innovation Research Institute (CHIRI) · Biomolecular ModellingAustralia · BentleyMolecular dynamics of folding and aggregation of Tau protein in Neurodegenerative disorders. Chemokine-GAG interactions. Insulin mimetics-insulin receptor interactions. Modelling of the effect of post-translational modifications on protein folding. -
Mar 2012–
Jul 2012Research: Postdoctoral fellow
Virginia Commonwealth University · Institute for Structural Biology and Drug Discovery · Umesh DesaiUSA · RichmondModelling interactions of heparin/heparan sulphate with chemokines. -
Aug 2011–
Feb 2012Research: Postdoctoral fellow
Curtin University Australia · School of Biomedical Sciences · Biomolecular ModellingAustralia · BentleyInteractions of glycosaminoglycans with proteins -
Jan 2009–
Dec 2012Research: Curtin University Australia
Curtin University Australia · School of Biomedical SciencesAustralia · Bentley -
Jan 2008
Research: Western Australian Institute for Medical Research Inc
Western Australian Institute for Medical Research IncAustralia · Perth -
Jan 2007–
Dec 2008Research: Zydus Research Centre
Zydus Research CentreIndia · Ahmadābād
Education
-
Feb 2008–
Jan 2012Curtin University Australia
Biomedical Sciences · Ph.D.Australia · Bentley -
Sep 2006–
Oct 2008Curtin University Australia
Biomedical Sciences · M.Phil.Australia · Bentley -
Aug 1997–
Jul 2001The Maharaja Sayajirao University of Baroda
Computer Science · B.E.India · Vadodara
Awards & achievements
-
Feb 2012Award: Commendation by Vice Chacellor for Best Ph.D. Thesis
-
Feb 2008Scholarship: CUPS
-
Feb 2008Scholarship: EIPRS
Other
-
LanguagesEnglish, Gujarati, Hindi
-
Scientific MembershipsMRACI CCHEM
-
Journal RefereesBioorganic & Medicinal Chemistry, Molecular Simulation, Bioorganic & Medicinal Chemistry Letters, Journal of Molecular Structure THEOCHEM, Current Medicinal Chemistry, Chemical Biology & Drug Design, Carbohydrate Polymers
Publications (22) View all
-
Article: Free energy calculations of the interactions of c-Jun-based synthetic peptides with the c-Fos protein.
[show abstract] [hide abstract]
ABSTRACT: The c-Fos-c-Jun complex forms the activator protein 1 transcription factor, a therapeutic target in the treatment of cancer. Various synthetic peptides have been designed to try to selectively disrupt the interaction between c-Fos and c-Jun at its leucine zipper domain. To evaluate the binding affinity between these synthetic peptides and c-Fos, polarizable and nonpolarizable molecular dynamics (MD) simulations were conducted, and the resulting conformations were analyzed using the molecular mechanics generalized Born surface area (MM/GBSA) method to compute free energies of binding. In contrast to empirical and semiempirical approaches, the estimation of free energies of binding using a combination of MD simulations and the MM/GBSA approach takes into account dynamical properties such as conformational changes, as well as solvation effects and hydrophobic and hydrophilic interactions. The predicted binding affinities of the series of c-Jun-based peptides targeting the c-Fos peptide show good correlation with experimental melting temperatures. This provides the basis for the rational design of peptides based on internal, van der Waals, and electrostatic interactions.Biopolymers 11/2012; 97(11):899-909. · 2.87 Impact Factor -
Article: Prediction of heparin binding sites in bone morphogenetic proteins (BMPs).
Neha S Gandhi, Ricardo L Mancera[show abstract] [hide abstract]
ABSTRACT: Heparin is a glycosaminoglycan known to bind bone morphogenetic proteins (BMPs) and the growth and differentiation factors (GDFs) and has strong and variable effects on BMP osteogenic activity. In this paper we report our predictions of the likely heparin binding sites for BMP-2 and 14. The N-terminal sequences upstream of TGF-β-type cysteine-knot domains in BMP-2, 7 and 14 contain the basic residues arginine and lysine, which are key components of the heparin/HS-binding sites, with these residues being highly non-conserved. Importantly, evolutionary conserved surfaces on the beta sheets are required for interactions with receptors and antagonists. Furthermore, BMP-2 has electropositive surfaces on two sides compared to BMP-7 and BMP-14. Molecular docking simulations suggest the presence of high and low affinity binding sites in dimeric BMP-2. Histidines were found to play a role in the interactions of BMP-2 with heparin; however, a pK(a) analysis suggests that histidines are likely not protonated. This is indicative that interactions of BMP-2 with heparin do not require acidic pH. Taken together, non-conserved amino acid residues in the N-terminus and residues protruding from the beta sheet (not overlapping with the receptor binding sites and the dimeric interface) and not C-terminal are found to be important for heparin-BMP interactions.Biochimica et Biophysica Acta 07/2012; 1824(12):1374-81. · 4.66 Impact Factor -
Article: Molecular modeling of Bt Cry1Ac (DI-DII)-ASAL (Allium sativum lectin)-fusion protein and its interaction with aminopeptidase N (APN) receptor of Manduca sexta.
Sunita Tajne, Ramadevi Sanam, Rambabu Gundla, Neha S Gandhi, Ricardo L Mancera, Dayakar Boddupally, Dashavantha Reddy Vudem, Venkateswara Rao Khareedu[show abstract] [hide abstract]
ABSTRACT: Genetic engineering of Bacillus thuringiensis (Bt) Cry proteins has resulted in the synthesis of various novel toxin proteins with enhanced insecticidal activity and specificity towards different insect pests. In this study, a fusion protein consisting of the DI-DII domains of Cry1Ac and garlic lectin (ASAL) has been designed in silico by replacing the DIII domain of Cry1Ac with ASAL. The binding interface between the DI-DII domains of Cry1Ac and lectin has been identified using protein-protein docking studies. Free energy of binding calculations and interaction profiles between the Cry1Ac and lectin domains confirmed the stability of fusion protein. A total of 18 hydrogen bonds was observed in the DI-DII-lectin fusion protein compared to 11 hydrogen bonds in the Cry1Ac (DI-DII-DIII) protein. Molecular mechanics/Poisson-Boltzmann (generalized-Born) surface area [MM/PB (GB) SA] methods were used for predicting free energy of interactions of the fusion proteins. Protein-protein docking studies based on the number of hydrogen bonds, hydrophobic interactions, aromatic-aromatic, aromatic-sulphur, cation-pi interactions and binding energy of Cry1Ac/fusion proteins with the aminopeptidase N (APN) of Manduca sexta rationalised the higher binding affinity of the fusion protein with the APN receptor compared to that of the Cry1Ac-APN complex, as predicted by ZDOCK, Rosetta and ClusPro analysis. The molecular binding interface between the fusion protein and the APN receptor is well packed, analogously to that of the Cry1Ac-APN complex. These findings offer scope for the design and development of customized fusion molecules for improved pest management in crop plants.Journal of molecular graphics & modelling 11/2011; 33:61-76. · 2.17 Impact Factor -
Article: Computational analyses of the catalytic and heparin-binding sites and their interactions with glycosaminoglycans in glycoside hydrolase family 79 endo-β-D-glucuronidase (heparanase).
[show abstract] [hide abstract]
ABSTRACT: Mammalian heparanase is an endo-β-glucuronidase associated with cell invasion in cancer metastasis, angiogenesis and inflammation. Heparanase cleaves heparan sulfate proteoglycans in the extracellular matrix and basement membrane, releasing heparin/heparan sulfate oligosaccharides of appreciable size. This in turn causes the release of growth factors, which accelerate tumor growth and metastasis. Heparanase has two glycosaminoglycan-binding domains; however, no three-dimensional structure information is available for human heparanase that can provide insights into how the two domains interact to degrade heparin fragments. We have constructed a new homology model of heparanase that takes into account the most recent structural and bioinformatics data available. Heparin analogs and glycosaminoglycan mimetics were computationally docked into the active site with energetically stable ring conformations and their interaction energies were compared. The resulting docked structures were used to propose a model for substrates and conformer selectivity based on the dimensions of the active site. The docking of substrates and inhibitors indicates the existence of a large binding site extending at least two saccharide units beyond the cleavage site (toward the nonreducing end) and at least three saccharides toward the reducing end (toward heparin-binding site 2). The docking of substrates suggests that heparanase recognizes the N-sulfated and O-sulfated glucosamines at subsite +1 and glucuronic acid at the cleavage site, whereas in the absence of 6-O-sulfation in glucosamine, glucuronic acid is docked at subsite +2. These findings will help us to focus on the rational design of heparanase-inhibiting molecules for anticancer drug development by targeting the two heparin/heparan sulfate recognition domains.Glycobiology 07/2011; 22(1):35-55. · 3.58 Impact Factor -
Article: Molecular dynamics simulations of CXCL-8 and its interactions with a receptor peptide, heparin fragments, and sulfated linked cyclitols.
Neha S Gandhi, Ricardo L Mancera[show abstract] [hide abstract]
ABSTRACT: CXCL-8 (Interleukin 8) is a CXC chemokine with a central role in the human immune response. We have undertaken extensive in silico analyses to elucidate the interactions of CXCL-8 with its various binding partners, which are crucial for its biological function. Sequence and structure analyses showed that residues in the thirdq β-sheet and basic residues in the heparin binding site are highly variable, while residues in the second β-sheet are highly conserved. Molecular dynamics simulations in aqueous solution of dimeric CXCL-8 have been performed with starting geometries from both X-ray and NMR structures showed shearing movements between the two antiparallel C-terminal helices. Dynamic conservation analyses of these simulations agreed with experimental data indicating that structural differences between the two structures at quaternary level arise from changes in the secondary structure of the N-terminal loop, the 3(10)-helix, the 30s, 40s, and 50s loops and the third β-sheet, resulting in a different interhelical separation. Nevertheless, the observation of these different states indicates that CXCL-8 has the potential to undergo conformational changes, and it seems likely that this feature is relevant to the mode of binding of glycosaminoglycan (GAG) mimetics such as cyclitols. Simulations of the receptor peptide fragment-CXCL-8 complex identified several specific interactions of the receptor peptide with CXCL-8 that could be exploited in the structure-based design of competitive peptides and nonpeptidic molecules targeting CXCL-8 for combating inflammatory diseases. Simulations of the CXCL-8 dimer complexed with a 24-mer heparin fragment and of the CXCL-8-receptor peptide complex revealed that Arg60, Lys64, and Arg68 in the dimer bind to cyclitols in a horseshoe pattern, defining a region which is spatially distinct from the receptor binding site. There appears to be an optimum number of sulfates and an optimum length of alkyl spacers required for the interaction of cyclitol inhibitors with the dimeric form of CXCL-8. Calculation of the binding affinities of cyclitol inhibitors reflected satisfactorily the ranking of experimentally determined inhibitory potencies. The findings of these molecular modeling studies will help in the search for inhibitors which can modulate various CXCL-8 biological activities and serve as an excellent model system to study CXC-inhibitor interactions.Journal of Chemical Information and Modeling 02/2011; 51(2):335-58. · 4.68 Impact Factor
About
My research interest involve molecular modelling of complex carbohydrates and their interactions (heparin/heparan sulphate) with proteins, and molecular dynamics simulations of folding and aggregation of disordered proteins.